27
Jun
Through the ‘i-Démo’ call for projects under the France 2030 plan, operated by Bpifrance on behalf of the French government, Cilcare is further consolidating its international leadership by being the first biotech to launch a diagnostic aid for synaptopathy and to clinically validate the efficacy of CIL001, an innovative drug for the treatment of this condition affecting 15% of the population.
Cilcare is one of 600 French companies to have been selected, and has received €4.2 million in...